ABVX:EPA
Abivax SA
€75.50
0.00%
(0.00) 1 天
11月17日, GMT+1 17:35:42 · EUR
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 ABVX 生成关键数据洞见…
市值
66.39亿
平均成交量
10.97万
成交量
0.00
52 周最高价
€139.00
52 周最低价
€60.45
每股收益
-€5.20
流通股数
8754.81万
员工人数
98
市值
66.39亿
平均成交量
10.97万
成交量
0.00
52 周最高价
€139.00
52 周最低价
€60.45
每股收益
-€5.20
流通股数
8754.81万
员工人数
98
新闻报道
来自网络来源和新闻合作伙伴
TradingView
·
1小时前
Stock Market: Will S&P 500 Open Up or Down Today?
Trefis
·
1小时前
1 S&P 500 Stock Just Made A New 52-Week High
Latest news from Azerbaijan
·
1小时前
Dow, S&P 500, Nasdaq futures extend losses for fourth session amid AI sell-off
资料
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA简介